These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31229029)

  • 1. Light of dawn in Melbourne: SONAR and CREDENCE.
    Nangaku M
    Kidney Int; 2019 Jul; 96(1):2-4. PubMed ID: 31229029
    [No Abstract]   [Full Text] [Related]  

  • 2. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.
    Heerspink HJL; Andress DL; Bakris G; Brennan JJ; Correa-Rotter R; Dey J; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray J; Perkovic V; Tobe S; Wigderson M; Parving HH; de Zeeuw D
    Diabetes Obes Metab; 2018 Jun; 20(6):1369-1376. PubMed ID: 29405626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The landscape of diabetic kidney disease transformed.
    Tuttle KR
    Nat Rev Nephrol; 2020 Feb; 16(2):67-68. PubMed ID: 31831876
    [No Abstract]   [Full Text] [Related]  

  • 4. CREDENCE: A silver lining in the dark cloud of diabetic nephropathy.
    Hanai K; Babazono T
    J Diabetes Investig; 2020 May; 11(3):527-529. PubMed ID: 31705732
    [No Abstract]   [Full Text] [Related]  

  • 5. How Does CREDENCE Inform Best Use of SGLT2 Inhibitors in CKD?
    Neumiller JJ; Kalyani RR
    Clin J Am Soc Nephrol; 2019 Nov; 14(11):1667-1669. PubMed ID: 31575617
    [No Abstract]   [Full Text] [Related]  

  • 6. Will Canagliflozin Lend Credence to the Potential Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Renal Endpoints in Diabetic Nephropathy.
    Neumiller JJ; Rhee CM; Kalantar-Zadeh K
    Am J Nephrol; 2017; 46(6):459-461. PubMed ID: 29227973
    [No Abstract]   [Full Text] [Related]  

  • 7. [In patients with type 2 diabetes and diabetic nephropathy with albuminuria, what is the effect of SGLT2 inhibitor canagliflozin on renal and cardiovascular outcomes?].
    Lanthier L; Huard G; Plourde MÉ; Cauchon M
    Rev Med Interne; 2020 Jan; 41(1):67-68. PubMed ID: 31812446
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic transformation for diabetic kidney disease.
    Tuttle KR; Cherney DZI
    Kidney Int; 2021 Feb; 99(2):301-303. PubMed ID: 33509348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diabetic Kidney Disease - How to Protect the Kidney?].
    Brenner S; Wanner C
    Dtsch Med Wochenschr; 2019 Jun; 144(11):710-714. PubMed ID: 31163466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research digest: SGLT2 inhibition in kidney and liver disease.
    Preiss D; Sattar N
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):427. PubMed ID: 31103176
    [No Abstract]   [Full Text] [Related]  

  • 11. Atrasentan: The Difficult Task of Integrating Endothelin A Receptor Antagonists into Current Treatment Paradigm for Diabetic Kidney Disease.
    Ortiz A; Fernandez-Fernandez B
    Clin J Am Soc Nephrol; 2021 Dec; 16(12):1775-1778. PubMed ID: 34853063
    [No Abstract]   [Full Text] [Related]  

  • 12. Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.
    Wanner C
    Nat Rev Nephrol; 2018 Feb; 14(2):78-80. PubMed ID: 29307892
    [No Abstract]   [Full Text] [Related]  

  • 13. Diabetic kidney disease in primary care.
    Fong JMN; Tsang LPM; Kwek JL; Guo W
    Singapore Med J; 2020 Aug; 61(8):399-405. PubMed ID: 32875340
    [No Abstract]   [Full Text] [Related]  

  • 14. Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?
    Fernandez-Fernandez B; Fernandez-Prado R; Górriz JL; Martinez-Castelao A; Navarro-González JF; Porrini E; Soler MJ; Ortiz A
    Clin Kidney J; 2019 Jun; 12(3):313-321. PubMed ID: 31198532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined effect of sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibitors for diabetic kidney disease.
    Araki SI
    J Diabetes Investig; 2020 Jan; 11(1):22-24. PubMed ID: 31520446
    [No Abstract]   [Full Text] [Related]  

  • 16. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
    Neuen BL; Young T; Heerspink HJL; Neal B; Perkovic V; Billot L; Mahaffey KW; Charytan DM; Wheeler DC; Arnott C; Bompoint S; Levin A; Jardine MJ
    Lancet Diabetes Endocrinol; 2019 Nov; 7(11):845-854. PubMed ID: 31495651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelin A receptor antagonists in diabetic kidney disease.
    Georgianos PI; Agarwal R
    Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):338-344. PubMed ID: 28520568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A
    Nadkarni GN; Takale D; Neal B; Mahaffey KW; Yavin Y; Hansen MK; Fleming F; Heerspink HJL; Coca SG
    Kidney360; 2022 Sep; 3(9):1599-1602. PubMed ID: 36245651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
    Mima A
    J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction.
    Heerspink HJL; Kohan DE; de Zeeuw D
    Kidney Int; 2021 Feb; 99(2):346-349. PubMed ID: 33144213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.